Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 1, 2014, Pages

  da Silva, Edina MK ^a   Strufaldi, Maria Wany Louzada ^a   Andriolo, Régis B ^b   Silva, Laercio A ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSIDADE DO ESTADO DO PARÁ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG ANTIBODY; GLYCOSAMINOGLYCAN; IDURONATE 2 SULFATASE; PLACEBO;

BODY HEIGHT; BODY WEIGHT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME REPLACEMENT; FORCED VITAL CAPACITY; HUMAN; HUNTER SYNDROME; INFUSION RELATED REACTION; LIVER WEIGHT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIX MINUTE WALK TEST; SPLEEN WEIGHT; SYSTEMATIC REVIEW; URINARY EXCRETION; DRUG ADMINISTRATION; ENZYMOLOGY; METHODOLOGY; RARE DISEASE;

DRUG ADMINISTRATION SCHEDULE; ENZYME REPLACEMENT THERAPY; HUMANS; IDURONATE SULFATASE; MUCOPOLYSACCHARIDOSIS II; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RARE DISEASES;

EID: 84903779290     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008185.pub3     Document Type: Review

References (32)

1. Beck M, Wraith E, Muenzer J, Giugliani R, Harmatz P, Eng CM, et al. Long-term weekly dosing of idursulfase in the treatment of mucopolysaccharidosis II (MPS II, Hunter syndrome) [abstract]. Journal of Inherited Metabolic Disease 2007;30(Suppl 1):116.
2. Muenzer J, Beck M, Eng CM, Giugliani R, Harmatz P, Martin R, et al. Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genetics in Medicine 2011;13(2):95-101.
3. Muenzer J, Wraith E, Beck M, Giugliani R, Harmatz P, Eng CM, et al. Clinical benefit of enzyme replacement therapy (ERT) in mucopolysaccharidosis II (MPS II, Hunter syndrome) [abstract]. Journal of Inherited Metabolic Disease 2006;29(Suppl 1):28.
4. Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genetics in Medicine 2006;8(8):465-73.
5. Gutiérrez-Solana LG. Clinical study of enzyme replacement therapy with idursulfase. Revista de Neurologia 2007;44(Suppl 1):S7-S11.
6. Muenzer J, Calikoglu MG, Conway AM, Kimura A. The long-term experience of enzyme replacement therapy for Hunter syndrome (MPS II) [abstract]. Journal of Inherited Metabolic Disorder 2005;28(Suppl 1):188.
7. Muenzer J, Gucsavas-Calikoglu M, McCandless SE, Schuetz TJ, Kimura A. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Molecular Genetics and Metabolism. 2007;90(3):329-37.
8. Muenzer J, Towle D, Calikoglu M, McCandless S. The 12-month experience of enzyme replacement for mucopolysaccharidosis II (Hunter syndrome) [abstract]. Journal of Inherited Metabolic Disease 2003;26(Suppl 2):144.
9. Sohn YB, Cho SY, Park SW, Kim SJ, Ko AR, Kwon EK, et al. Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome). Orphanet Journal of Rare Diseases 2013;8:42. [DOI: ]
10. Tylki-Szymanska A, Giugliani R, Hwu WL. A clinical trial of idursulfase in Hunter syndrome patients 5 years old and younger [abstract]. Journal of Inherited Metabolic Disease 2008;31(Suppl 1):130.
11. Alcalde-Martín C, Muro-Tudelilla JM, Cancho-Candela R, Gutiérrez-Solana LG, Pintos-Morell G, Martí-Herrero M, et al. First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: Case observations from the Hunter Outcome Survey (HOS). European Journal of Medical Genetics 2010;53(6):371-7.
12. American Thoracic Society. ATS statement: guidelines for the six-minute walk test. American Journal of Respiratory and Critical Care Medicine 2002;166(1):111-7.
13. de Jong JG, Wevers RA, Liebrand-van Sambeek R. Measuring urinary glycosaminoglycans in the presence of protein: an improved screening procedure for mucopolysaccharidoses based on dimethylmethylene blue. Clinical Chemistry 1992;38(6):803-7.
14. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9. [PUBMED: 11914310]
15. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003;327(7414):555-7.
16. Higgins JPT, Altman DG. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
17. Higgins JPT, Deeks JJ, Altman DG. Chpater 16: Special topics in statistics. Intention to treat issues. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
18. Jones SA, Almássy Z, Beck M, Burt K, Clarke JT, Giugliani R, et al. Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS). Journal of Inherited Metabolic Disease 2008;32(4):534-43.
19. Jones SA, Parini R, Harmatz P, Giugliani R, Fang J, Mendelsohn NJ, et al. The effect of idursulfase on growth in patients with Hunter syndrome: data from the Hunter Outcome Survey (HOS). Molecular Genetics and Metabolism 2013;109(1):41-8.
20. Kresse H, von Figura K, Klein U, Glossl J, Paschke E, Pohlmann R. Enzymic diagnosis of the genetic mucopolysaccharide storage disorders. Methods in Enzymology 1982;83:559-72.
21. Martin R, Beck M, Eng C, Giugliani R, Harmatz P, Munoz V, et al. Recognition and Diagnosis of Mucopolysaccharidosis II (Hunter Syndrome). Pediatrics 2008;121(2):e377-86.
22. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999;281(3):249-54.
23. Muenzer J, Beck M, Eng CM, Giugliani R, Harmatz P, Martin R, et al. Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genetics in Medicine 2011;13(2):95-101.
24. National Horizon Scanning Centre. New and Emerging Technology Briefing: Iduronate-2-sulfatase for Hunter Syndrome. The University of Birmingham 2005.
25. Neufeld EF, Muenzer J. The mucopolysaccharidoses. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill, 2001:3421-52.
26. Schulze-Frenking G, Jones SA, Roberts J, Beck M, Wraith JE. Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II. Journal of Inherited Metabolic Disease 2011;34(1):203-8.
27. Tuschl K, Gal A, Paschke E, Kircher S, Bodamer OA. Mucopolysaccharidosis type II in females: case report and review of literature. Pediatric Neurology 2005;32(4):270-2.
28. Vellodi A, Wraith JE, Cleary M, Ramaswami U, Lavery C, Jessop E. Guidelines for the investigation and management of patients with mucopolysaccharidosis type II. www.specialisedservices.nhs.uk/library/23/Guidelines_for_Mucopolysaccharidosis_Type_II.pdf (accessed September 2009).
29. Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, Guffon N, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. European Journal of Pediatrics 2008;167(3):267-77.
30. Wraith JE. Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II. Acta Paediatrica. Supplementum 2008;97(497):76-8.
31. Young ID, Harper PS. The natural history of the severe form of Hunter's syndrome: a study based on 52 cases. Developmental Medicine and Child Neurology 1983;25(4):481-9.
32. da Silva EMK, da Silva EMK, Strufaldi MWL, Andriolo RB, Silva LA. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome). Cochrane Database of Systematic Reviews 2011, Issue 11. [DOI: ]